High-dose FOLFIRI (irinotecan 260 mg/m2 for UGT1A1*1/*1 and *1/*28 genotypes and 220 mg/m2 for UGT1A1*28/*28 genotypes) combined with cetuximab has been explored in a multicentre phase II study (ERBIFORT) in patients with potentially resectable liver metastases of CRC.23 This regimen yielded high response rates and enabled complete resection of hepatic metastases in most patients. This evidence concerns the gene UGT1A1 and colorectal carcinoma.